Select a category
Kohl's Cuts Costs To Address A Challenging Consumer Environment
Kohl’s (KSS) Shares Rose Wednesda...
Investopedia
2 s
13
:max_bytes(150000):strip_icc()/INV_Kohls_Store_GettyImages-1487130596-92a3628d0758420e844c707826224620.jpg)
Kohl’s (KSS) shares rose Wednesday as cost reduction helped the retailer beat profit forecasts despite a drop in sales.
Kohl’s reported second-quarter earnings per share (EPS) of 59 cents, 14 cents above the average estimate of analysts surveyed by Visible Alpha. Revenue fell 4.2% to $3.5 billion and comparable store sales slipped 5.1%. Both figures were below expectations. Selling, general, and administrative (SG&A) expenses also declined 4.2%, to $1.2 billion.
Kohl’s now sees full-year revenue down 6%, compared with an earlier prediction of a 4% fall. But it lifted its profit outlook for the year, to a range of $1.75 to $2.25 a share, up from a previous forecast of $1.25 to $1.85 per share.
Kohl's anticipates that full-year comparable store sales will fall 5% versus the previous expectation of a decrease of 3%.
Shares of Kohl's, which edged higher Wednesday, have lost nearly a third of their value this year.
Chief Executive Officer Tom Kingsbury said his company has taken “significant action to reposition Kohl’s for future growth.” However, he said the gains were muted in part because of “a continued challenging consumer environment and softness in our core business.”
Kingsbury added that during the quarter, shoppers “exhibited more discretion in their spending.” Even so, he said, the company’s “conviction in our strategy remains strong.”
Do you have a news tip for Investopedia reporters? Please email us at [email protected]Read more on Investopedia
Instablog9ja
59 m
11
Single Nigerian women have placed their hands on their chest as rapper Falz uploaded a picture of him on ‘father duties.
The singer has uploaded a picture of himself with his child to the amazement of his fans.
Here's Why A Handful Of Pharmaceutical Stocks Rose Wednesday
Shares Of Several Drugmakers And Bi...
Investopedia
60 m
14
:max_bytes(150000):strip_icc()/GettyImages-19805223281-bae720bc6952496091a40da32bf01617.jpg)
Shares of several drugmakers and biotechnology firms moved higher on Wednesday, notching some of the day's top performances in the S&P 500.
Various regulatory decisions and clinical trial results boosted the top-performing pharmaceutical stocks: Gilead Sciences (GILD), Bristol-Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX).
Shares of Gilead Sciences rose about 2%, extending a multiday string of gains that has followed the approval of Livdelzi, a treatment for inflammatory liver disease that received clearance from the Food and Drug Administration (FDA) on Aug. 14. Gilead has also drawn positive attention for its portfolio of HIV treatments.
Bristol-Myers Squibb (BMY) shares added close to 2% after competitor Neurocrine Biosciences (NBIX) released mixed results from a mid-stage clinical trial of its schizophrenia treatment. Although a low dose of Neurocrine's drug helped reduce the severity of schizophrenia symptoms, the study raised concerns about whether the benefits would carry over in larger trials. Bristol-Myers Squibb's schizophrenia treatment KarXT is set for an approval decision from the FDA in September.
Vertex Pharmaceuticals (VRTX) shares were up almost 2% after the company said the FDA approved its new drug application for suzetrigine, an oral treatment designed to alleviate moderate to severe pain. The drug has reportedly been granted a priority evaluation from the regulator, with a projected action date of Jan. 30.
While much of the market's attention has been focused on blockbuster weight-loss treatments from Eli Lilly (LLY) and Novo Nordisk (NVO), overall stock market returns in the industry have been relatively subdued this year. The SPDR S&P Pharmaceuticals ETF (XPH) is up around 7% in 2024, compared with gains of roughly 17% for the S&P 500.
Do you have a news tip for Investopedia reporters? Please email us at [email protected]Read more on Investopedia
Instablog9ja
2 hrs
15
A 30-year-old man identified as Chinonso Ezekiel Nwaebonyi has been arrested for defiling his neighbor’s 7-year-old daughter.
It is reported that the incident happened in Awka, the capital of Anambra State. The mother of the victim reported the matter to the Ministry of Women’s Affairs after discovering it while bathing her daughter.
The mother (name withheld) said that while bathing her daughter one day, she noticed that her pr+vate area was swollen. When she inquired, her daughter accused Nwaebonyi. She said the defilement had been a regular occurrence and always happened when her daughter and her twin brothers went to play in the paedophile’s compound.
She added that she took her daughter to a pharmacy where she bought her dr¥gs and also complained to the guardian of Nwaebonyi before reporting to the ministry’s officials, who later arrested him.
The suspect, an indigene of Izzi in Ebonyi State, confessed to the crime but claimed he did it only once. He was quoted as saying, “I never f%rced the girl, but only asked her to raise her clothes and lie down on the ground.”
As of the time of filing this report, the suspect had been handed over to the police for prosecution.
Investopedia
2 hrs
15
:max_bytes(150000):strip_icc()/GettyImages-20187459501-1370dcc1683342849ba1ec6858fafe02.jpg)
Nvidia (NVDA) reported better-than-expected revenue and earnings for the second quarter of fiscal 2025, though the pace of its growth slowed. Shares fell in extended trading Wednesday following the release.
The chipmaker reported second-quarter revenue of $30 billion, more than doubling from the year-ago period. Net income for the fiscal second quarter was $16.6 billion, also more than double its value the year prior. Both figures exceeded analysts' expectations compiled by Visible Alpha, though growth slowed from previous quarters.
Data center revenue for the fiscal second quarter was $26.3 billion, setting a new record high and more than doubling from the year prior.
"Hopper demand remains strong, and the anticipation for Blackwell is incredible," Nvidia CEO Jensen Huang said, adding that the chipmaker "achieved record revenues as global data centers are in full throttle to modernize the entire computing stack with accelerated computing and generative AI."
After concerns about reported delays in Nvidia’s Blackwell AI chip sent Nvidia's stock price tumbling earlier this month, the chipmaker said Wednesday it began shipping some samples of its Blackwell chip in the second quarter, and expects to "ship several billion dollars in Blackwell revenue" during the fourth quarter as production ramps up.
The chipmaker gave a stronger-than-expected outlook for the third quarter of fiscal 2025, with revenue expected to be around $32.5 billion.
Nvidia's board also approved a new $50 billion share buyback plan. The company said it had $7.5 billion worth of previously authorized repurchases as of the end of the first half.
Despite Nvidia's earnings and revenue beat, the chipmaker's stock was down over 5% at $118.40 in extended trading Wednesday following the company's earnings release.
Do you have a news tip for Investopedia reporters? Please email us at [email protected]Read more on Investopedia
Instablog9ja
3 hrs
12
Businesswoman Sophia Momodu throws shad£ at you-know-who as she shares throwback picture of her trip to Disneyland with her daughter, Imade
She said 1yr ago today she fulfilled a promise that was intentionally broken to a child because not Sophia’s daughter chile.
